Four retrospective studies have previously demonstrated that patients with hypopituitarism have an increased rate of death compared with control patients matched for age, but the exact cause of this is unknown. Analysis is difficult because hypopituitarism has many causes, patients undergo various treatments that may contribute to the outcome (surgery, radiotherapy and drug therapy) and each study has had limitations. In the study reported here, Tomlinson et al. used the West Midlands Hypopituitarism database (representing about 10% of the British population) to look for the cause of death over an 8-year period in 514 men and 500 w om e n w ith hy p op itu ita rism (p ati en ts wi th acromegaly, Cushing's disease and metastatic disease affecting the pituitary were excluded from the outset because of the known association with excess mortality in these conditions).
Excess mortality was found in patients with hypopituitarism compared with a control population and was shown to be caused by respiratory, cardiovascular and cerebrovascular disease. The increased rate of death compared with a control group was roughly similar for each of these body systems. The rate of malignancy was not increased. The young (<60 years) women and those who had u ntr ea ted go na do tro p hin de fic ien cy h ad a n in cr eas ed m or tal ity rate co m pa re d w ith a background population (contrary to current opinion in the case of gonadotrophin deficiency). The presence of a craniopharyngioma was associated with particularly poor outcome. Patients who underwent surgery had excess mortality when compared with those who did not, whilst radiotherapy was associated with increased death related to cerebrovascular disease. Tomlinson et al. speculate that these findings may have been because patients undergoing these treatments had more extensive disease and may not necessarily have b een ca us ed b y th e m eth o d of t rea tm en t. Surprisingly, and again contrary to current opinion, patients with growth hormone deficiency did not display excess mortality but Tomlinson et al. believe that the numbers enrolled were too small to display an effect. Tomlinson et al. were unable to explain the cause of the excess mortality, even though this had been a highly detailed and lengthy analysis of a large cohort of patients. It seems that there will need to be a large, prolonged multinational trial to answer questions about correct management and cause of death.
J This study considers three aspects of the clinical use of human chorionic gonadotrophic (hCG) immunoassays: (1) method-related differences in recognition of purified hCG-related molecules;
(2) method-related differences in the apparent 'hCG concentration' measured in sera from patients with trophoblastic disease; and (3) vulnerability of different methods to false positive results. Serum samples from 59 patients with confirmed trophoblastic disease (8 with choriocarcinoma, 51 with complete hydatidiform mole -30 with serum hCG>500 U/L, 21 with serum hCG<500 U/L) and from 12 women with previously reported false positive hCG results were blindly tested in six commercially available hCG immunoassays and one double antibody radioimmunoassay (RIA). Also included in the panel were five samples containing purified preparations of hCG-related molecules (hyperglycosylated hCG, nicked hCG, asialo hCG, hCG lacking the C-terminal peptide, and non-nicked hCG-subunit). A total of four laboratory centres contributed to the study, the different centres each contributing a different range of assay methods.
Results obtained for the purified hCG-related molecules confirmed the well-recognised difficulties involved in measuring 'mixtures'. All these immunoassays were calibrated in terms of the current International Standard for intact hCG, so differences in their recognition of hCG-related m olecules were not unexpected. H owever, it should be noted that the clinical relevance of some of the hCG-related molecules used in this study remains to be established.
Results for the 59 patient serum samples demonstrated some significant between-method differences in results, significant difference here being defined as results deviating from the RIA method by more than 25%. The extent to which the study design may have contributed to these differences is difficult to assess from the data reported. For example, most 'errors', unsurprisingly, were recorded with a method marketed (appropriately) as an 'intact' hCG assay. In addition, it is not clear whether the specimens were despatched at ambient temperature or on dry ice (to ensure stability in transit, particularly important for hCG), and what assay precision was achieved.
Results for the 12 serum samples from patients w ith a h isto ry of f alse po sitiv e h C G r esu lts reported by other labs, most of whom had been subjected to needless surgery or chemotherapy, confirmed that the raised results first reported for these serum samples were spuriously high (i.e. false positive) when tested again using the same method. Similarly, high results were also seen in a proportion of the samples when tested by four other methods, although two methods showed no false positives.
In the original article reporting results for these women (Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed m alignant disease in women with false positive human chorionic gonadotrophin concentrations. Lancet 2000; 355: 712-5), the authors implied that the errors were due to heterophilic antibody interference. However, the presence of heterophilic antibodies was not conclusively demonstrated, as could perhaps have been done using blocking tubes or by re-assaying in the presence of mouse IgG. The Lancet report was accompanied by a thoughtp ro vo kin g co m m en tar y ( B ag sh aw e KD . L im ita tio ns o f tes ts f or hu m an ch or ion ic gonadotrophin. Lancet 2000; 355: 671) . This suggested that the problem of inadequate assays and lack of information relating to them is particularly relevant in countries where services for patients with trophoblastic disease have not been formally centralized, as they have been for more than 25 years in the United K ingdom . These countries include the USA, Germany and Spain.
However, putting aside the above reservations , 2000) proposes to address these difficulties by developing pathology at a regional level instead of the current, district-based system . Wh ilst seeming to endorse the regional organisation of pathology, Professor Lilleyman suggests that the way forward for UK pathology is to re-examine the highly compartmentalized nature of the service, to reject duplication of effort and to restructure the funding of pathology so that it reflects workload. Prof Lilleyman does not, however, go so far as to step into the European field. Instead, he advocates a cautionary approach to change, on the basis that the quality of pathology in the UK is high and that pathology disciplines will serve their local community better by responding to local geography and local configuration of clinical services. It seems inevitable that there will be change. It is up to us as a profession to deal with it.
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